BioCryst Pharmaceuticals develops and sells medicines for hereditary angioedema and other rare diseases. BCRX reports earnings on Wed, Nov 4, 2026. Analyst consensus is Buy, based on the latest ratings from 4 firms (2 buy, 2 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 30 | JP Morgan | Target raised | Hold | |
| Sep 10 | RBC Capital | Downgrade | Hold | |
| Sep 8 | Needham | Reiterated | Buy | |
| Aug 6 | Wedbush | Maintained | Buy | |
| Jul 13 | JP Morgan | Reinstated | Hold |
Seasonality
How BCRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in BCRX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BCRX is in one of them and how their past BCRX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BCRX in an article yet. Here's the latest on the wider market.
BCRX Congress Trades
All congress trades →
| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Jul 10, 2026 | Sep 4, 2026 | 56 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Nov 13, 2025 | Dec 15, 2025 | 32 d |
| Josh GottheimerD · NJ | Buy | $1K – $15K | Oct 16, 2023 | Nov 11, 2023 | 26 d |
| Josh GottheimerD · NJ | Sell | $1K – $15K | Sep 15, 2023 | Oct 15, 2023 | 30 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Biocryst Pharmaceuticals
BioCryst Pharmaceuticals is a biotechnology company based in Durham, North Carolina. It develops and sells medicines for hereditary angioedema and other rare diseases. Its main product, ORLADEYO, is an oral medicine taken once daily to prevent attacks of hereditary angioedema, and it is approved in the United States and several other markets. The company also has RAPIVAB, an intravenous treatment for influenza, approved in several countries. Its customers include patients with these conditions, along with the healthcare providers and insurers who support their care.
- Headquarters
- Durham, NC
- Founded
- 1986
- Website
- biocryst.com ↗